Directorio

We are doing this study to find out if the experimental combination of the drugs finalimab and cemiplimab (the study drugs) is a safe and effective option for people with high-risk melanoma. We want to see how well the study drugs work compared to treatment with pembrolizumab.

We are doing this study to learn more about the long-term effectiveness of an approved medicine that is prescribed for the treatment of EoE. We want to know how will dupilumab (Dupixent®) works over time when EoE patients and their doctors choose it as therapy. Dupilumab was approved by the FDA in May 2022 to treat EoE and was the first drug approved for this purpose.

We are doing this study to find out if an experimental study drug called RP1 (the study drug) is a safe and effective option for people who have advanced melanoma. We want to know how the study drug works when it is combined with a cancer drug called nivolumab in comparison to several other standard treatments for advanced melanoma (nivolumab + relatlimab OR nivolumab alone OR pembrolizumab alone).

We are doing this study to find out if an experimental drug called RP2 (the study drug) is a safe and effective option for people who have uveal melanoma (melanoma in the eye). We want to know how well the study drug works when it is combined with a drug called nivolumab, and we will compare its outcomes to treatment with the drug combination of nivolumab + ipilimumab.

We are doing this study to find out if a drug called rosuvastatin (an FDA-approved medication for lowering cholesterol) can help reduce symptoms and extend the life expectancy of people with liver cirrhosis. Although rosuvastatin is an approved and commonly prescribed drug, it is not approved for the treatment of cirrhosis.

If you choose to join this study, you will first give your permission and take part in some starting tests. These include answering questions, doing fitness checks, and completing movement tasks. After that, you will be randomly placed into one of three groups: one group will do aerobic exercise, another will receive brain stimulation called rTMS, and the third group will do both. Each group will follow a 12-week treatment plan. After that, there will be follow-up check-ins at 12 weeks and again at 24 weeks. The entire study will last about 9 months.

We are doing this study to find out if an investigational drug named VRDN-003 (the study drug) is a safe and effective option for patients with thyroid eye disease (TED).